newsfilter
← Earnings
Earnings Releases·

Immix Biopharma — Third Quarter 2026 Earnings Summary

  • Cash and marketable securities increased to $340.9 million as of September 30, 2026, from $234.1 million in June 2026, extending the operating runway into mid-2028.
  • The company reported a net loss of $13.9 million for the quarter, a reduction from $35.6 million over the nine-month period, with total operating expenses of $15.9 million for the quarter.
  • Interim NXC-201 data from the NEXICART-2 trial demonstrated an 89% complete response rate across 45 patients, supporting plans to submit a BLA in mid-2027 and initiate the NEXICART-3 front-line trial in the first half of 2027.
  • Senior leadership appointments were made to lead Technical Operations and Regulatory Affairs, leveraging experience from approved BCMA CAR-T products to accelerate commercial launch readiness.
Company
IMMIX BIOPHARMA INC
Sector
Healthcare
Industry
Biotechnology